TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04854499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously
Study: NCT05426681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlyBURIDE Oral Tablet
Description: Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide
Study: NCT05985174

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CD64 , HLA-DR
Description: CD64 is atype of integral membrane glycoprotein , when activated , it increases the neutrophils' potential for phagocytosis and bacterial killing .~HLA-DR is on the surface of monocyte\\macrophages , dendritic cells and plays a crucial role in adaptive immune response
Study: NCT05818007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: sodium bicarbonate solution
Study: NCT06403150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam Injection
Description: Levetiracetam at 60 mg/kg (max dose 4500 mg) will be intravenously administered in 100mL of normal saline at an administration rate of 2-5mg/kg/min or over 10 minutes. After 30 minutes following Levetiracetam needle time reassessment of the patient will be done to determine the outcomes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin Injection
Description: Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
Study: NCT05678127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken.
Study: NCT04605055

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
Study: NCT06265233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Improv sessions
Description: Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
Study: NCT06674499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help rehabilitation model
Description: The intervention measures followed the principles and processes of cognitive-behavioral therapy. Three intervention sessions were conducted over a period of eight weeks. The first session lasted 90 minutes, while the subsequent sessions (in weeks 4 and 8) lasted 45 minutes each and were conducted face-to-face by the therapist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional rehabilitation model
Description: The control group, which follows the conventional rehabilitation model, operates under the current standard of cancer treatment and follow-up. In this model, oncology healthcare professionals provide recommendations based on the specific circumstances of the patients. However, the choice of the rehabilitation model is primarily decided by the patients themselves, aligning with current clinical practice.
Study: NCT06265233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exposure and Response Prevention (ERP) Therapy
Description: Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
Study: NCT06366022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The tunnel technique for root coverage with CTG with inner side of the graft
Description: Procedure: The tunnel technique for root coverage with CTG with inner side of the graft

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The tunnel technique for root coverage with CTG with outer side of the graft
Description: The tunnel technique for root coverage with CTG with outer side of the graft
Study: NCT05802836

Intervention type: OTHER
Intervention: no interventions
Description: no intervention, only 3 different patients groups

Intervention type: OTHER
Intervention: no interventions
Description: no intervention, only 3 different patients groups

Intervention type: OTHER
Intervention: no interventions
Description: no intervention, only 3 different patients groups
Study: NCT05613179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group1 (lever positioning manipulation)
Description: The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group2 (placebo group)
Description: The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
Study: NCT05950997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg capsules administered by mouth once daily (28-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
Study: NCT04523519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy with contingency management
Description: PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Integrated Next-Step Counseling
Description: Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Next-Step Counseling
Description: Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
Study: NCT06296030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POOF ACT program
Description: The goal of this study is to test this culturally tailored intervention (POOF) against classic ACT, to discover if POOF does better at decreasing race-based trauma in African Americans.Guided by the cultural humility framework and social determinants of health model, we examine POOF, a culturally-tailored ACT model for use with anxious African Americans. The POOF approach builds on research on ACT for the general population, an evidence-based intervention, by tailoring the language of ACT while retaining the fidelity of the ACT model. Our hypotheses examine acceptability and attitudes toward treatment, treatment outcomes for psychological symptoms (i.e., anxiety) and an ACT-related outcome (i.e., psychological flexibility), and a possible underlying mechanism of change (i.e., race-based stress).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classic ACT program
Description: This protocol is for a classic, non-adapted ACT intervention.
Study: NCT06569329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleWave System Root Canal Therapy
Description: This device has 510k market approval for its intended use within this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EdgePro Laser Root Canal Therapy
Description: This device has 510k market approval for its intended use within this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy
Description: This device has 510k market approval for its intended use within this study.
Study: NCT06570590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive lapidus procedure with no arthroscopy
Description: The two procedures, with and without arthroscopy, only differ by the method of assessing cartilage removal. Cartilage removal will be assessed arthroscopically in the procedure with arthroscopy. In the procedure without arthroscopy, cartilage removal will be assessed via direct visualization through a mini arthrotomy procedure. After use of the cartilage burr the surgeon will make a small dorsal portal and use this opening to ensure that the cartilage is removed and all debris removed. The incision will be 2 cm long and centered over the dorsal medial aspect of the joint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive lapidus procedure with arthroscopy
Description: After removal of the cartilage with the cartilage burr, a 3.0 arthroscope will be inserted to inspect the joint for all cartilage removal. Any residual cartilage pieces will be removed to ensure complete cartilage debridement from the subchondral bone and fragments removed from the joint.
Study: NCT06064162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: 60mg (.5mg/kg over 40 minutes intravenously)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ketamine
Description: 60mg (.5mg/kg over 40 minutes intravenously)
Study: NCT06002685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-Up
Description: The ABC program consists of 10 one-hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic. Principal intervention activities include a discussion of basic attachment principles, guided practice of new parenting behaviors, and a review of video clips from previous sessions to help reinforce parenting targets. The parent coach promotes (a) nurturance, especially in response to distress; (b) following the child's lead with delight; and (c) avoiding frightening caregiving behavior. As specified by the ABC protocol, any/all other family members will be invited to observe or participate in each ABC session Each full-time ABC parent coach will serve 8 to 10 families at a time (i.e., complete 8-10 hourly ABC visits per week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Book-of-the-Week
Description: The HBOW program is an active control condition developed by PI Berlin. It consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. During each of the 10 weeks, a trained RA will visit each HBOW mother to drop off the book and to ask briefly about the mother's and child's well-being (using a standard set of questions). Thus, this condition will parallel the intervention condition in duration (number of weeks) and structure, although it will be less intensive in terms of participant contact time per visit.
Study: NCT05742178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) - More Intensive
Description: The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation (PN) - Less Intensive
Description: The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.
Study: NCT06625723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative care
Description: This will include medications, rehabilitation schedules, and follow-up visits as normally scheduled.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard postoperative care
Description: This will include medications, rehabilitation schedules, and follow-up visits as normally scheduled.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Recovery Systems Sleep Aid
Description: Sleep assistive device
Study: NCT06682962

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) with the OkuStim 2 System
Description: Retinal stimulation is achieved through transcorneal current application: using a thread electrode, a weak current (≤ 1mA) is introduced onto the surface of the eye, which spreads through the eye towards the retina.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) with the OkuStim 2 System
Description: Retinal stimulation is achieved through transcorneal current application: using a thread electrode, a weak current (≤ 1mA) is introduced onto the surface of the eye, which spreads through the eye towards the retina.
Study: NCT06618729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein
Description: Ingestion of a meal containing 40 g of protein from pea protein extrudate
Study: NCT06571825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: The consolidation therapy involves a regimen of intermediate-dose cytarabine (Ara-C) combined with Ven, specifically Ara-C at 1.0 g/m²/day for 3 days (days 1-3) and Ven at 400 mg/day for 10 to 14 days (days 1-10 to 14), with each cycle lasting 4 to 6 weeks, for a total of 3 consolidation cycles. This is followed by maintenance therapy with azacitidine (AZA) at 50 mg/m²/day for 5 days (days 1-5), with each cycle lasting 4 weeks, for a total of 6 maintenance cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic transplant
Description: The consolidation therapy involves allo-HSCT, with the choice of conditioning regimens typically using reduced-intensity conditioning such as the Fludarabine+Busulfan (FluBu) or Fludarabine+Melphalan (FluMel) regimens commonly used by centers, which can also include Ven.~FluBu regimen: Flu 30 mg/m²/day from day -10 to day -5, Bu 3.2 mg/kg/day from day -6 to day -5 or day -7 to day -5, antithymocyte globulin (ATG) (e.g., rabbit ATG at a total dose of 6-7.5 mg/kg, administered from day -4 to day -1), and Ven from day -10 to day -4.~FluMel regimen: Flu 30 mg/m²/day from day -10 to day -5, Mel 50-70 mg/m²/day from day -4 to day -3, ATG and Ven from day -10 to day -4.~12 weeks (±4 weeks) post-HSCT maintenance begins with AZA at 32 mg/m²/day for 5 days (days 1-5), with each lasting 6 weeks, for a total of 6 cycles. Donor lymphocyte infusion is allowed in cases of minimal residual disease (MRD) positivity.
Study: NCT06569225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
Description: : Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase
Study: NCT06190275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT201 in combination with PD-1 inhibitors
Description: GT201 in combination with a PD-1 inhibitor for advanced (HNSCC)
Study: NCT04601337

Intervention type: PROCEDURE
Intervention: Infrared Neural Stimulation
Description: We will stimulate nerves identified for transfer or grafting over a range of simulation parameters (pulse width, spot size, energy per unit area, etc) to determine the stimulation threshold. Only portions of the nerve that are no longer functionally required will be stimulated optically. Successful INS events will be determined by visual muscle contractions. Stimulation thresholds will be determined by fitting the data to a cumulative distribution function. Stimulation sites on the nerve will be harvested and histologically examined for evidence of INS-induced damage.
Study: NCT06014723

Intervention type: PROCEDURE
Intervention: Submaximal balloon angioplasty
Description: The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
Study: NCT06618729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat protein
Description: Ingestion of a meal containing 40 g of protein from wheat protein extrudate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: Ingestion of a meal containing 40 g of protein from soy protein extrudate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chicken
Description: Ingestion of a meal containing 40 g of protein from chicken
Study: NCT05388825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 2.5mg
Description: TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study: NCT06692257

Intervention type: BEHAVIORAL
Intervention: Observation
Description: To perform a comparative analysis of orofacial functions with an emphasis on breathing and chewing patterns in individuals with and without MIH.

Intervention type: BEHAVIORAL
Intervention: Observation
Description: To perform a comparative analysis of orofacial functions with an emphasis on breathing and chewing patterns in individuals with and without MIH.
Study: NCT06692946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooperative Parent-Mediated therapy
Description: Parent-mediated therapy is an intervention where parents are trained to use therapeutic techniques to support their child's development and manage symptoms, often used for conditions like autism spectrum disorder (ASD).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatement as Usual
Description: Cognitive Behavioral Therapy (CBT) is a structured, short-term psychological treatment that focuses on identifying and changing negative thought patterns and behaviors. It aims to help individuals develop healthier ways of thinking and coping with challenges by addressing both cognitive (thought) and behavioral components.~Parent training is an educational intervention where parents learn strategies and techniques to effectively manage their child's behavior and support their development, often used to address challenges associated with conditions like autism or ADHD.
Study: NCT05539352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST) plus EUC
Description: All caregivers are assigned to this condition and receive EUC and PST. EUC is delivered along with the treatment to ensure the safety of all caregivers enrolled in the study. In addition to EUC, caregivers receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by caregivers and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress.